Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate induced robust immune responses in nonhuman primates. H5N1 is a highly ...

T he Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Two large US investments in human vaccines for the H5N1 avian flu are aimed at improving readiness in the case of a pandemic. The US Department of Health and Human Services (HHS), through the ...

The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in ...

These so-called pandemic vaccine viruses are an essential line of defense against the threat of an avian flu pandemic. They can be used to create vaccines to help reduce severe illness.

The vaccine’s efficacy was 26.6% higher than GSK’s flu shot in the ... of an mRNA-based bird flu vaccine, as well as the right to purchase this vaccine. This funding loss comes at a ...